B
Bull
Bull · 25%CCCC
$2.05
情境價格
$3.850
-0.235 (-6.10%)收盤時
Loading chart…
- High
- 4.100
- Open
- 4.070
- VWAP
- 3.93
- Vol
- 1.83M
- Mkt Cap
- 317.88M
- Low
- 3.830
- Amount
- 7.18M
- EV/EBITDA, TTM
- 0.26
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
估值指標
The current forward P/E ratio for C4 Therapeutics Inc (CCCC) is -1.37, compared to its 5-year average forward P/E of -4.26.
Alphio AI Price Scenarios for CCCC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding CCCC
事件時間軸
資訊
9.508-13NASDAQ.COMC4 Therapeutics Reports Narrowed Losses and Revenue Growth in Q2
8.506-01NASDAQ.COMReplimune Receives FDA Support for BLA Resubmission
8.505-29seekingalphaC4 Therapeutics Hits 52-Week High Following BMY's Positive Myeloma Trial Results
9.505-12seekingalphaC4 Therapeutics Q1 Earnings Beat Expectations with Revenue of $6.15M
7.504-09seekingalphaC4 Therapeutics Partners with Roche to Develop Novel Cancer Drugs
CCCC FAQ — answered by Alphio AI
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。